| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |